And you keep blathering about the clear superiority of Cymerus when their only published result is a 15 subject phase 1 from 2018 that has disappeared since then. How on earth does that compare with 400 patients p.a. treated?
And you keep blathering about MSB's cash burn ("Money Silviu Burns") as being inferior to CYP's careful guarding of its cash.
Yes, it costs hundreds of millions to develop a product to market. MSB is in that game. Takes commitment and guts to do that. How about your stem cell passion? They'd love a straw to clutch at.
Mesoblast in Freefall, page-478
-
- There are more pages in this discussion • 505 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |